Industry News

Global pharma major Lupin Limited announced the launch of Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06%, in the United States.

Novartis has announced the top-line results of its Phase III GCAptAIN study, evaluating Cosentyx (secukinumab) in patients with giant cell arteritis (GCA) a serious inflammatory condition that primarily affects adults over the age of 50.

Vertex Pharmaceuticals has announced that the European Commission has approved its newest cystic fibrosis treatment, ALYFTREK a once-daily, triple-combination therapy made up of deutivacaftor, tezacaftor, and vanzacaftor.

In a significant development for global health, Hyderabad-based Biological E. Limited has joined hands with Chinese biopharmaceutical firm Jiangsu Recbio Technology Company Limited to produce and distribute the 9-valent Human Papillomavirus (HPV9) vaccine, REC603.

Alembic Pharmaceuticals Limited has announced that it has received final approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Doxorubicin Hydrochloride Liposome Injection in two strengths: 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) single-dose vials.

As reported by Reuters, U.S. pharmaceutical giant Eli Lilly has launched its Mounjaro KwikPen in India, expanding its portfolio of treatments for diabetes and obesity.

Glenmark Pharmaceuticals Ltd., a research-driven global pharmaceutical company, has announced the launch of TEVIMBRA® (tislelizumab) in India, marking its official entry into the immuno-oncology segment.

Emcure Pharmaceuticals has announced that its Board of Directors has approved a proposal to acquire the remaining 20.42% minority stake in its subsidiary, Zuventus Healthcare Ltd. The acquisition will result in Zuventus becoming a wholly owned subsidiary of Emcure.